Bioanalytical and CMC Services for the life science industry
The Kymos Group is an analytical CRO with three European laboratories devoted to providing bioanalytical and CMC services for the life science industry throughout the entire product life cycle: from early research and development to manufacturing and commercialization. We are GLP- and GMP-certified, have been successfully inspected by the EMA and the FDA and are experts in analytical and quality control work with small molecules, biologics and oligonucleotides. Kymos provides services to clients worldwide in the pharmaceutical, biotechnology, veterinary, fine chemistry, cosmetic and nutraceutical industries.
Testimonials
“We are currently developing multiple new biosimilar projects and consider Kymos one of the best CROs in Europe for drug release and testing.”
“We were positively impressed when Kymos reacted to our needs by investing in their stability capabilities, and now, two years down the line, with projects in full-swing, I can safely say that we made the right choice. In Kymos we have found a reliable, committed, trustworthy and professional partner.”
“Back in 2017 there weren’t many analytical CROs able to carry out Franz cell assays and Kymos’ pioneering work was pivotal for the registration of our product.”
“Kymos offered superior historical expertise by being exposed to so many different clients, pharmacological compounds, and therapeutic areas. They addressed and anticipated very diverse problems.”
“I have had a long and fruitful experience with Kymos and have a huge interest in their participation owing to their reliability.”
“Prolytic is our analytical partner throughout the entire drug development process. Such a long and complex process requires a laboratory you can trust. Professional yet flexible, Prolytic accompanies us through the preclinical and clinical phases.”
“Establishing robust miRNA methods for valuable results is tricky. The team at Prolytic have been a key collaboration partner. With their 30 years of experience in bioanalytics and broad know-how in different techniques, study types, and substance groups, we were able to quickly develop a reproducible and reliable analysis method for miRNAs.”
Latest News
FDA New Guidance: NDSRIs Recommended Acceptable Intake Limits
The US Food and Drug Administration (FDA) has taken a significant step to address the mutagenic and carcinogenic risk associated with Nitrosamine Drug Substance-Related Impurities (NDSRIs). This past August, the FDA introduced a final guidance (...) Read more
VICH GL18 (R2): Changes in Residual Solvents for Veterinary Products
As stated by the EMA (European Medicines Agency), residual solvents are organic volatile chemicals used or produced during the manufacture of active substances or excipients, as well as in the preparation of veterinary medicinal products. (...) Read more
Subscribe here to be updated in the latest regulatory, technological and innovation news.
